Novo Nordisk A/S
SELECTIVE ELIMINATION OF EROSIVE CELLS
Last updated:
Abstract:
The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
Status:
Application
Type:
Utility
Filling date:
18 Dec 2019
Issue date:
9 Apr 2020